[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2018007704A - Composicion farmaceutica que comprende lenalidomida amorfa y un antioxidante. - Google Patents

Composicion farmaceutica que comprende lenalidomida amorfa y un antioxidante.

Info

Publication number
MX2018007704A
MX2018007704A MX2018007704A MX2018007704A MX2018007704A MX 2018007704 A MX2018007704 A MX 2018007704A MX 2018007704 A MX2018007704 A MX 2018007704A MX 2018007704 A MX2018007704 A MX 2018007704A MX 2018007704 A MX2018007704 A MX 2018007704A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
antioxidant
amorphous lenalidomide
treatment
pharmaceutically acceptable
Prior art date
Application number
MX2018007704A
Other languages
English (en)
Inventor
Vivancos Martinez Marta
Alvarez Fernandez Lisardo
Velada Calzada Jose
Original Assignee
Synthon Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon Bv filed Critical Synthon Bv
Publication of MX2018007704A publication Critical patent/MX2018007704A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que comprende lenalidomida amorfa, o una sal farmacéuticamente aceptable de la misma, con un antioxidante sintético y uno o más excipientes farmacéuticamente aceptables; la invención se refiere además al procedimiento para fabricar tales composiciones y al uso de dicha composición como un medicamento, particularmente en el tratamiento del mieloma múltiple y síndromes mielodisplásicos.
MX2018007704A 2015-12-22 2016-12-22 Composicion farmaceutica que comprende lenalidomida amorfa y un antioxidante. MX2018007704A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15202069 2015-12-22
PCT/EP2016/082318 WO2017109041A1 (en) 2015-12-22 2016-12-22 Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant

Publications (1)

Publication Number Publication Date
MX2018007704A true MX2018007704A (es) 2018-11-09

Family

ID=55068830

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018007704A MX2018007704A (es) 2015-12-22 2016-12-22 Composicion farmaceutica que comprende lenalidomida amorfa y un antioxidante.

Country Status (7)

Country Link
US (2) US10328028B2 (es)
EP (1) EP3393457A1 (es)
AU (1) AU2016378482A1 (es)
CL (1) CL2018001705A1 (es)
EA (1) EA036205B1 (es)
MX (1) MX2018007704A (es)
WO (1) WO2017109041A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3233059A1 (en) * 2014-12-19 2017-10-25 Synthon B.V. Pharmaceutical composition comprising amorphous lenalidomide
US20170107216A1 (en) 2015-10-19 2017-04-20 Incyte Corporation Heterocyclic compounds as immunomodulators
SG10202004618TA (en) 2015-11-19 2020-06-29 Incyte Corp Heterocyclic compounds as immunomodulators
MD3394033T2 (ro) 2015-12-22 2021-04-30 Incyte Corp Compuși heterociclici ca imunomodulatori
US20170320875A1 (en) 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2017205464A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
BR112018076534A2 (pt) 2016-06-20 2019-04-02 Incyte Corporation compostos heterocíclicos como imunomoduladores
WO2018013693A1 (en) * 2016-07-13 2018-01-18 Celgene Corporation Solid dispersions and cocrystals comprising 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione compositions and methods of use thereof
ES2930092T3 (es) 2016-07-14 2022-12-07 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
EP3504198B1 (en) 2016-08-29 2023-01-25 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018119236A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
TWI798192B (zh) 2016-12-22 2023-04-11 美商英塞特公司 免疫調節劑化合物及使用方法
MA47120A (fr) 2016-12-22 2021-04-28 Incyte Corp Dérivés pyridine utilisés en tant qu'immunomodulateurs
UA126394C2 (uk) 2016-12-22 2022-09-28 Інсайт Корпорейшн Похідні бензоксазолу як імуномодулятори
WO2019081749A1 (en) 2017-10-26 2019-05-02 Synbias Pharma Ag IMMEDIATE RELEASE FORMULATIONS OF LENALIDOMIDE
WO2019138424A1 (en) * 2018-01-11 2019-07-18 Natco Pharma Limited Stable pharmaceutical compositions comprising lenalidomide
CN112135824B (zh) 2018-03-30 2024-11-05 因赛特公司 作为免疫调节剂的杂环化合物
WO2019199136A1 (ko) * 2018-04-13 2019-10-17 주식회사 삼양바이오팜 붕해가 개선된 레날리도마이드의 경구용 정제 조성물
MD3790877T2 (ro) 2018-05-11 2023-08-31 Incyte Corp Derivați de tetrahidro-imidazo[4,5-c]piridină în calitate de imunomodulatori PD-L1
JP2022544189A (ja) 2019-08-09 2022-10-17 インサイト・コーポレイション Ｐｄ－１／ｐｄ－ｌ１阻害剤の塩
CN115175734B (zh) 2019-09-30 2024-04-19 因赛特公司 作为免疫调节剂的吡啶并[3,2-d]嘧啶化合物
IL292524A (en) 2019-11-11 2022-06-01 Incyte Corp Salts and crystalline forms of pd-1/pd-l1 inhibitor
CN110664761A (zh) * 2019-11-18 2020-01-10 杭州百诚医药科技股份有限公司 一种来那度胺药物组合物及其制备方法
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
WO2022099075A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Crystalline form of a pd-1/pd-l1 inhibitor
TW202233616A (zh) 2020-11-06 2022-09-01 美商英塞特公司 用於製備ｐｄ－１／ｐｄ－ｌ１抑制劑以及其鹽及結晶形式之方法
CN117098531A (zh) * 2021-01-08 2023-11-21 斯塔顿治疗公司 用于肠胃外使用的免疫调节酰亚胺化合物的稳定溶液

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA60308C2 (uk) 1996-07-24 2003-10-15 Селджін Корпорейшн ЗАМІЩЕНІ 2-(2,6-ДІОКСОПІПЕРИДИН-3-ІЛ)ФТАЛІМІДИ ТА 1-ОКСОІЗОІНДОЛІНИ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ЗНИЖЕННЯ РІВНЯ ФПН-α
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
CN101959856A (zh) 2008-03-11 2011-01-26 雷迪博士实验室有限公司 来那度胺的制备
CN102272118A (zh) 2008-11-03 2011-12-07 基因里克斯(英国)有限公司 来那度胺的晶型及其制备方法
EP2355802A1 (de) * 2008-11-14 2011-08-17 Ratiopharm GmbH Intermediate und orale darreichungsformen enthaltend lenalidomid
DK2403845T3 (da) * 2009-03-02 2014-08-04 Generics Uk Ltd Forbedret proces.
CN101537184B (zh) * 2009-04-30 2011-04-20 杭州中美华东制药有限公司 一种含水难溶高活性药物的组合物及其制备方法
EP2545043B1 (en) 2010-03-08 2019-04-24 Natco Pharma Limited Anhydrous lenalidomide form-i
US20150126582A1 (en) * 2012-04-30 2015-05-07 Sevion Therapeutics, Inc. Combination Treatment of Multiple Myeloma
US9808450B2 (en) * 2013-03-26 2017-11-07 Celgene Corporation Solid forms comprising 3-(4-amino-1-OXO-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione and a coformer, compositions and methods of use thereof
CN103705485B (zh) * 2013-12-31 2015-07-22 广州帝奇医药技术有限公司 一种用于治疗骨髓增生异常综合症的组合物及其制备方法

Also Published As

Publication number Publication date
US10328028B2 (en) 2019-06-25
EP3393457A1 (en) 2018-10-31
CL2018001705A1 (es) 2018-08-10
EA201891489A1 (ru) 2018-11-30
US11007152B2 (en) 2021-05-18
EA036205B1 (ru) 2020-10-14
WO2017109041A1 (en) 2017-06-29
US20190240157A1 (en) 2019-08-08
US20180256501A1 (en) 2018-09-13
AU2016378482A1 (en) 2018-07-12

Similar Documents

Publication Publication Date Title
MX2018007704A (es) Composicion farmaceutica que comprende lenalidomida amorfa y un antioxidante.
MX2021009673A (es) Moduladores de ror-gamma.
PH12017500583A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
PH12016501457A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
PH12021551189A1 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
PH12016501830A1 (en) Inhibitors of c5a for the treatment of viral pneumonia
WO2016040952A3 (en) BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
PH12018500358A1 (en) Compounds for use in an antibacterial applications
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
EP3288636A4 (en) COMPOSITIONS FOR THE TREATMENT OF EPISTAXIS
PH12016501997B1 (en) Cycloalkyl-linked diheterocycle derivatives
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2017008983A (es) Composición farmaceútica de sulfonamida.
WO2015001541A3 (en) Pharmaceutical film composition
MX2015013151A (es) Métodos de tratamiento de disquinesia y trastornos relacionados.
MX2017013879A (es) Composiciones que comprenden anakinra.
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
MX2018005134A (es) Formulacion de factor viii (fviii).
PH12020500045A1 (en) Novel composition of enzalutamide oral dosage form and method of manufacturing thereof
IN2013MU03428A (es)
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.
IN2013MU01226A (es)